BIGBEAR Pharmaceutical announces the approval of Larotrectinib in Laos

Date:2024-07-04 Views: 52 Times

Vientiane, Laos - May 30, 2024 - BigBear Pharma, a leading biopharmaceutical company focused on developing and commercializing innovative cancer treatments, today announced that Larotrectinib have been approved by the Ministry of Health of Laos.

Approved drugs are: Larotrectinib sold under the brand name LARODX. 

  • Lao registered trade name: Lao Reg No.: 04L1086/24 100mg
  • Lao registered trade name: Lao Reg No.: 04L1087/24 25mg

Larotrectinib is an inhibitor of tropomyosin kinase receptors TrkA, TrkB, and TrkC. Larotrectinib was initially awarded orphan drug status in 2015, for soft tissue sarcoma, and breakthrough therapy designation in 2016 for the treatment of metastatic solid tumors with NTRK fusion.Some clinical trial results were announced in 2017. On 26 November 2018, Larotrectinib was approved by the FDA.

Retrieved July 03,2024, From

About NTRK Fusion-Positive Solid Tumors

Neurotrophic tyrosine receptor kinase (NTRK) gene fusions are an actionable biomarker for cancer therapy and can be found in over 25 different types of cancer, regardless of where they are located in the body. NTRK fusion-positive tumors have been identified in a broad range of solid tumor types, including breast, cholangiocarcinoma, colorectal, gynecological, neuroendocrine, non-small cell lung, salivary gland, pancreatic, sarcoma and thyroid cancers.

How are NTRK fusion-positive tumors treated?

Recent advances in personalized medicine mean that NTRK fusion-positive tumors may be appropriate for treatment with a targeted medicine regardless of the type of cancer or where it originated. This is called a tumor-agnostic treatment approach.